Who is sponsoring NCT01797276?

NCT01797276 is sponsored by University of Florida.

What drugs are being tested in NCT01797276?

Interventions in NCT01797276: Dichloroacetate.

What condition does NCT01797276 study?

NCT01797276 studies Mitochondrial Enzyme Deficiencies.

Is NCT01797276 still recruiting?

NCT01797276 is currently no longer available. Last updated 8 August 2017.

Last reviewed 2017-08-08 · How we verify

NCT01797276: CLA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access

NO LONGER AVAILABLE Last updated 8 August 2017

What this trial tests

trial testing Dichloroacetate in Mitochondrial Enzyme Deficiencies. No longer available.

Quick facts

Lead sponsor	University of Florida
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	1 location across United States

Drugs / interventions tested

Dichloroacetate — full drug profile →

Conditions studied

Mitochondrial Enzyme Deficiencies — all drugs for Mitochondrial Enzyme Deficiencies →

Sponsor

University of Florida

Who can join

Adults 18 to 50, female only, with Mitochondrial Enzyme Deficiencies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Expanded access to DCA as continued treatment for congenital lactic acidosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dichloroacetate

Trials testing the same drug.

NCT05317455 — Regulation of Brain Glucose Metabolism in Type 1 Diabetes · EARLY_PHASE1 · recruiting
NCT04046081 — A Clinical Trial to Evaluate Dichloroacetate (DCA) as a Treatment for Endometriosis-associated Pain · NA · completed
NCT03356457 — Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes · EARLY_PHASE1 · completed

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01797276 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 8 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01797276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing